**UCI Gavin Herbert Eye Institute 18th Annual Colloquium**

September 6, 2024

**Purpose**

**Friday, September 6, 7:00 a.m. – 6:00 p.m.
Saturday, September 7, 7:00 a.m. – 1:00 p.m.**

**In-person:** Arnold and Mabel Beckman Center, 100 Academy Way, Irvine, CA 92617

The UCI Gavin Herbert Eye Institute will lead its 18th annual colloquium on Friday and Saturday, September 6-7, 2024. The program will be structured to be dynamic and interactive, addressing topics of particular importance to current comprehensive ophthalmic practice. Presenting faculty includes UC Irvine Ophthalmology clinical and research faculty, and guest speakers covering topics such as cataract, retina, refractive, plastic & orbital surgery, glaucoma, neuro-ophthalmology, pediatrics and cornea & ocular diseases. In addition to lectures, extensive case presentations will be used to facilitate discussions and to encourage interactive learning.

**Topics:**

* Latest refractive technologies reviewed: LASIK, SMILE, ICL, etc.
* Interactive biostatistics refresher for the clinician
* Running the gamut on presbyopia-correcting IOLs
* Introducing minimally invasive micro sclerostomy
* Optimize outcomes in diabetic tractional retinal detachments
* Update in lens selection in complex eyes
* Intravitreal injections in the management of geographical atrophy
* Pearls for iris repair
* Diagnosis and treatment options for tearing
* The advent of Rho kinase inhibitors
* Eyelid malposition treatment
* Neuro-ophthalmic mimickers of disease
* Drug delivery systems for glaucoma treatment
* Uveitis, ocular oncology, pediatric updates, and more!
* Dry eyes/blepharitis skills transfer lab

**CME Event Evaluation and Certificate Notes:**

You must complete a brief evaluation of our event in order to receive your CME certificate. This will be uploaded following the event.

Please note that this evaluation must be completed and **submitted online via CloudCME by November 12, 2024**. This is the only way to confirm your attendance, which is required in order to receive CME credit.

**Target Audience**

Specialties – Ophthalmology

Professions – Physician, Medical Assistant, Medical Student, Other, Resident Physician

**Activity Objectives**

1 Identify common neuro-ophthalmic mimickers of thyroid eye disease

1 Describe various options for diagnosing and treating tearing due to poor outflow mechanisms

2 Outline approaches to management of eyelid malpositions

2 Calculate for and manage astigmatism in complex corneas

3 Understand in office corneal procedures to prepare for cataract surgery

4 Identify the indications and techniques for intraocular lens exchange

4 Discuss upcoming drug delivery options in the management of glaucoma

5 Review updates in the medical management of geographic atrophy

5 Choose between drops, minimally invasive surgery and lasers in glaucoma

6 Test for and treat dry eye and ocular surface disease in 2024

**Accreditation Statement**

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Live Activity for a maximum of 9.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.









**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Dana Collinson, BA | Activity Administrator | Nothing to disclose - 06/17/2024 |
| Stephanie Lu, MD | Faculty | Nothing to disclose - 06/26/2024 |
| Matthew Wade, MD | Co-Director, Faculty | Consulting Fee-Johnson & Johnson|Consulting Fee-Vialase|Consulting Fee-Glaukos|Consulting Fee-Centricity Vision - 01/23/2024 |
| Lilangi Ediriwickrema, MD | Co-Director, Faculty | Nothing to disclose - 07/10/2024 |
| Sumit (Sam) Garg, MD | Faculty | Consulting Fee-Johnson & Johnson|Consulting Fee-Aldeyra|Consulting Fee-AbbVie (Any division)|Consulting Fee-BVI|Consulting Fee-Centricity Vision (Relationship has ended)|Consulting Fee-CorneaGen|Honoraria-Dompe|Honoraria-Expert Opinion|Consulting Fee-Emmecell|Advisor-ForSight Robotics|Consulting Fee-Glaukos|Consulting Fee-Hoya (Relationship has ended)|Consulting Fee-Kala|Advisor-LensGen|Ownership-OcuTrx|Consulting Fee-Rayner|Consulting Fee-Sight Sciences|Consulting Fee-Samsara|Advisor-SpyGlass|Consulting Fee-Tarsus|Consulting Fee-Trefoil (Relationship has ended)|Consulting Fee-Verana Health (Relationship has ended)|Consulting Fee-Versea|Consulting Fee-Visus|Consulting Fee-Vista Ophthalmics|Consulting Fee-Zeiss - 08/05/2024 |
| Jeremiah Tao, MD | Faculty | Nothing to disclose - 07/08/2024 |
| Austin Fox, MD | Faculty | Paid consultant-New World Medical (Relationship has ended)|Paid consultant-Alcon (Any division) (Relationship has ended) - 08/22/2024 |
| Soroosh Behshad, MD | Faculty | Nothing to disclose - 06/30/2024 |
| Ken Y. Lin, MD, PhD | Faculty | Consulting Fee-Alcon (Any division)|Consulting Fee-Microsurgical Tehcnology|Advisor-Recursion Pharmaceuticals - 07/15/2024 |
| Andrew K. Smith, MD | Faculty | Consulting Fee-Alcon (Any division) - 07/31/2024 |
| Samuel J Spiegel, MD | Faculty | Nothing to disclose - 06/29/2024 |
| Mitul Mehta, MD | Faculty | Consulting Fee-AbbVie (Any division)|Consulting Fee-Astellas (Any division)|Consulting Fee-Alimera|Consulting Fee-Apellis|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eyedaptic |Grant or research support-jCyte|Consulting Fee-Zeiss - 08/19/2024 |
| Kapil Mishra, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-AbbVie (Any division)|Consulting Fee-Zeiss|Consulting Fee-Bausch & Lomb (Any division) - 07/31/2024 |
| Baruch D Kuppermann, MD, PhD, Director, Gavin Herbert Eye Institute | Faculty | Speakers Bureau-Allergan|Speakers Bureau-Coherus|Speakers Bureau-Genentech (Any division)|Speakers Bureau-Roche (Any division)|Grant or research support-Allergan|Grant or research support-Apellis|Grant or research support-Clearside|Grant or research support-Genentech (Any division)|Grant or research support-Ionis Pharmaceuticals|Grant or research support-IVERIC Bio|Grant or research support-Novartis Corporation Pharmaceuticals|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-RegenXBio|Consulting Fee-Alkeus|Consulting Fee-Allegro Ophthalmics|Consulting Fee-Allergan|Consulting Fee-Amgen, Inc.|Consulting Fee-Apellis|Consulting Fee-Astellas (Any division)|Consulting Fee-Aviceda Therapeutics|Consulting Fee-Clearside|Consulting Fee-Coherus|Consulting Fee-EyeBio|Consulting Fee-Eyedaptic|Consulting Fee-Genentech (Any division)|Consulting Fee-Glaukos Corporation|Consulting Fee-InflammX Therapeutics|Consulting Fee-IVERIC Bio|Consulting Fee-jCyte|Consulting Fee-Mobius|Consulting Fee-Molecular Partners|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Ocular Therapeutix|Consulting Fee-Oculis|Consulting Fee-Priviterra|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-ReVana Therapeutics|Consulting Fee-Ripple Therapeutics|Consulting Fee-Roche (Any division)|Consulting Fee-Santen|Consulting Fee-Stealth Therapeutics|Consulting Fee-TechImmune|Consulting Fee-Theravance Biopharma|Consulting Fee-Visgenix - 08/19/2024 |
| Mohammad Riazi Esfahani , MD | Faculty | Nothing to disclose - 08/01/2024 |
| Vivek Patel, MD  | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Horizon Pharmaceuticals - 08/20/2024 |
| Robert W. Crow, MD | Faculty | Nothing to disclose - 06/26/2024 |
| Sally L Baxter, MD, Gavin Herbert Lecturer | Faculty | Honoraria-Topcon|Other: Equipment Support-Optomed - 08/26/2024 |
| Christina Y. Weng, MD, MBA | Faculty | Consulting Fee-AbbVie (Any division)|Consulting Fee-Alcon (Any division)|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Genentech (Any division)|Consulting Fee-REGENXBIO|Consulting Fee-Astellas (Any division)|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Zeiss|Consulting Fee-Alimera Sciences|Consulting Fee-EyePoint|Independent Contractor (included contracted research)-DRCR Retina Network|Independent Contractor (included contracted research)-Alimera Sciences|Independent Contractor (included contracted research)-AGTC|Royalties or Patent Beneficiary-Springer Publishers - 08/04/2024 |
| Daniel Chang, MD | Faculty | Consulting Fee-Allergan|Grant or research support-Allergan|Speakers Bureau-Allergan|Consulting Fee-Atia Vision|Grant or research support-Bausch & Lomb (Any division)|Consulting Fee-Carl Zeiss Meditec|Speakers Bureau-Carl Zeiss Meditec|Consulting Fee-Johnson & Johnson|Grant or research support-Johnson & Johnson|Speakers Bureau-Johnson & Johnson|Consulting Fee-Omega Ophthalmics|Stocks or stock options, excluding diversified mutual funds-Omega Ophthalmics|Stocks or stock options, excluding diversified mutual funds-Atia Vision|Consulting Fee-Z Optics|Stocks or stock options, excluding diversified mutual funds-Z Optics - 07/02/2024 |
| Sanjay Kedhar, MD | Faculty | Consulting Fee-Visus Therapeutics|Consulting Fee-Glaukos|Consulting Fee-ANI Pharmaceuticals|Speakers Bureau-ANI Pharmaceuticals|Consulting Fee-Alcon (Any division)|Independent Contractor (included contracted research)-Priovant|Independent Contractor (included contracted research)-Krystal Bio|Independent Contractor (included contracted research)-Tarsier Pharma - 08/29/2024 |
| Donny W. Suh, MD | Faculty | Nothing to disclose - 08/26/2024 |
| Seanna Grob, MD | Faculty | Nothing to disclose - 07/10/2024 |
| Donny Suh, MD, MBA | Faculty | Nothing to disclose - 08/20/2024 |
| Andrew Browne, MD, PhD | Faculty | Grant or research support-Alcon (Any division)|Grant or research support-Carl Zeiss Meditec - 08/28/2024 |
| Charlotte Gore, MD | Faculty | Nothing to disclose - 07/24/2024 |
| Olivia L Lee, MD | Faculty | Consulting Fee-Cloudbreak Therapeutics|Other: Lecture Fees-CorneaGen|Other: Lecture Fees-Recordati Rare Diseases - 08/19/2024 |
| Sameh Mosaed, MD | Faculty | Consulting Fee-Skye biosciences|Grant or research support-SIghtScences|Advisor-Alcon (Any division) - 08/19/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

The University of California, Irvine School of Medicine would like to thank the following companies for their financial support of this educational activity:

Carl Zeiss

Genentech

Johnson & Johnson

Regeneron